Efficacy and Safety of Maintenance Therapy Using Cetuximab in Patients with Metastatic Colorectal Cancer: Retrospective Study

References

• Sung H, Ferlay J, Siegel R, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• O’Connell J, Maggard M, Ko C. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420–1425. doi:10.1093/jnci/djh275
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Oliveira J. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;61–63. doi:10.1093/annonc/mdp130
   PubMedGoogle Scholar
• Sonbol M, Mountjoy L, Firwana B, et al. The role of maintenance strategies in metastatic colorectal cancer: a systematic review and network meta-analysis of randomized clinical trials. JAMA Oncol. 2020;6(3):e194489. doi:10.1001/jamaoncol.2019.4489
   PubMed Web of Science ®Google Scholar
• Lenz H, Ou F, Venook A, et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2019;37(22):1876–1885. doi:10.1200/jco.18.02258
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal L, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, Phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075. doi:10.1016/s1470-2045(14)70330-4
   PubMed Web of Science ®Google Scholar
• Wang L, Liu Y, Yin X, et al. Effect of reduced-dose capecitabine plus cetuximab as maintenance therapy for RAS wild-type metastatic colorectal cancer: a Phase 2 clinical trial. JAMA Network Open. 2020;3(7):e2011036. doi:10.1001/jamanetworkopen.2020.11036
   PubMed Web of Science ®Google Scholar
• Simkens L, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385(9980):1843–1852. doi:10.1016/s0140-6736(14)62004-3
   PubMed Web of Science ®Google Scholar
• Hegewisch-Becker S, Graeven U, Lerchenmüller C, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015;16(13):1355–1369. doi:10.1016/s1470-2045(15)00042-x
   PubMed Web of Science ®Google Scholar
• Aranda E, García-Alfonso P, Benavides M, et al. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. Eur J Cancer. 2018;101:263–272. doi:10.1016/j.ejca.2018.06.024
   PubMed Web of Science ®Google Scholar
• Cremolini C, Antoniotti C, Lonardi S, et al. Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a randomized Phase 2 clinical trial. JAMA Oncol. 2018;4(4):529–536. doi:10.1001/jamaoncol.2017.5314
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Morano F, Corallo S, et al. Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a Phase 2 randomized clinical trial. JAMA Oncol. 2019;5(9):1268–1275. doi:10.1001/jamaoncol.2019.1467
   PubMed Web of Science ®Google Scholar
• Yalcin S, Uslu R, Dane F, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: Phase III “Stop and Go” study results--a Turkish Oncology Group Trial. Oncology. 2013;85(6):328–335. doi:10.1159/000355914
   PubMed Web of Science ®Google Scholar
• Díaz-Rubio E, Gómez-España A, Massutí B, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012;17(1):15–25. doi:10.1634/theoncologist.2011-0249
   PubMed Web of Science ®Google Scholar
• Matsuda A, Yamada T, Jamjittrong S, et al. Comparison between biweekly and weekly cetuximab in patients with metastatic colorectal cancer: a meta-analysis. Anticancer Res. 2020;40(6):3469–3476. doi:10.21873/anticanres.14333
   PubMed Web of Science ®Google Scholar
• Zekri J, Abbas Baghdadi M, Belal Ibrahim R, Meliti A, Sobahy TM. Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer. ecancermedicalscience. 2022;16. doi:10.3332/ecancer.2022.1490
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Sorbye H, Qvortrup C, et al. Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: the NORDIC-7.5 study by the Nordic Colorectal Cancer Biomodulation Group. Clin Colorectal Cancer. 2015;14(3):170–176. doi:10.1016/j.clcc.2015.03.002
   PubMed Web of Science ®Google Scholar
• Wasan H, Meade A, Adams R, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol. 2014;15(6):631–639. doi:10.1016/s1470-2045(14)70106-8
   PubMed Web of Science ®Google Scholar
• Jiang T, Chen H, Zheng J, et al. Cetuximab maintenance therapy in patients with unresectable wild-type RAS and BRAF metastatic colorectal cancer: a Single-Institute Prospective Study. Adv Ther. 2020;37(6):2829–2840. doi:10.1007/s12325-020-01360-8
   PubMed Web of Science ®Google Scholar
• Piessevaux H, Buyse M, Schlichting M, et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2013;31(30):3764–3775. doi:10.1200/jco.2012.42.8532
   PubMed Web of Science ®Google Scholar
• Cremolini C, Loupakis F, Antoniotti C, et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol. 2015;26(6):1188–1194. doi:10.1093/annonc/mdv112
   PubMed Web of Science ®Google Scholar
• Bouchahda M, Boige V, Smith D, et al. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. Eur J Cancer. 2016;68:163–172. doi:10.1016/j.ejca.2016.09.011
   PubMed Web of Science ®Google Scholar
• Chiappa A, Makuuchi M, Lygidakis N, et al. The management of colorectal liver metastases: expanding the role of hepatic resection in the age of multimodal therapy. Crit Rev Oncol Hematol. 2009;72(1):65–75. doi:10.1016/j.critrevonc.2008.11.003
   PubMed Web of Science ®Google Scholar
• Ksienski D, Woods R, Speers C, Kennecke H. Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC). Ann Surg Oncol. 2010;17(12):3085–3093. doi:10.1245/s10434-010-1304-9
   PubMed Web of Science ®Google Scholar
• Ye L, Wei Y, Zhu D, Chen T, Xu J. Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab. J Gastroenterol Hepatol. 2015;30(4):674–679. doi:10.1111/jgh.12847
   PubMed Web of Science ®Google Scholar
• Douillard J, Siena S, Peeters M, Koukakis R, Terwey J, Tabernero J. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2015;51(10):1231–1242. doi:10.1016/j.ejca.2015.03.026
   PubMed Web of Science ®Google Scholar
• Roth L, Russo L, Ulugoel S, et al. Peritoneal metastasis: current status and treatment options. Cancers. 2021;14(1):60. doi:10.3390/cancers14010060
   PubMed Web of Science ®Google Scholar
• Ceelen W, Ramsay R, Narasimhan V, Heriot A, De Wever O. Targeting the tumor microenvironment in colorectal peritoneal metastases. Trends Cancer. 2020;6(3):236–246. doi:10.1016/j.trecan.2019.12.008
   PubMed Web of Science ®Google Scholar
• Mendoza-Moreno F, Diez-Alonso M, Matías-García B, et al. Prognostic factors of survival in patients with peritoneal metastasis from colorectal cancer. J Clin Med. 2022;11(16):4922. doi:10.3390/jcm11164922
   PubMed Web of Science ®Google Scholar
• Franko J, Shi Q, Meyers J, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709–1719. doi:10.1016/s1470-2045(16)30500-9
   PubMed Web of Science ®Google Scholar